Improve Medical Instruments Co., Ltd. (SHE:300030)
China · Delayed Price · Currency is CNY 7.78
+0.08 (1.04%)
Apr 16, 2026, 3:04 PM CST
SHE:300030 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 486.26 | 575.33 | 635.17 | 705.16 | 793.98 |
Other Revenue | - | 5.99 | 9.45 | 5.61 | 5.86 |
| 486.26 | 581.33 | 644.62 | 710.77 | 799.83 | |
Revenue Growth (YoY) | -16.35% | -9.82% | -9.31% | -11.14% | -12.99% |
Cost of Revenue | 277.14 | 368.51 | 414.5 | 474.56 | 490.54 |
Gross Profit | 209.12 | 212.81 | 230.12 | 236.21 | 309.29 |
Selling, General & Admin | 140.33 | 180.76 | 225.16 | 239.4 | 219.24 |
Research & Development | 23.65 | 31.9 | 37.52 | 43.67 | 42.33 |
Other Operating Expenses | 3.29 | 6.11 | 4.03 | 4.96 | 7.08 |
Operating Expenses | 167.27 | 242.72 | 263.62 | 297.12 | 276.4 |
Operating Income | 41.85 | -29.91 | -33.5 | -60.91 | 32.89 |
Interest Expense | - | -11.09 | -16.56 | -19.7 | -25.44 |
Interest & Investment Income | 20.48 | 1.82 | 8.55 | 2.45 | 20.76 |
Currency Exchange Gain (Loss) | - | 1.2 | -0.84 | 2.38 | -1.56 |
Other Non Operating Income (Expenses) | 3.69 | 0.67 | -3.51 | -2.11 | -6.53 |
EBT Excluding Unusual Items | 66.02 | -37.31 | -45.87 | -77.89 | 20.11 |
Impairment of Goodwill | - | -11.87 | -2.93 | -53.62 | - |
Gain (Loss) on Sale of Investments | -10.17 | -63.56 | 1.21 | -53.1 | 6.41 |
Gain (Loss) on Sale of Assets | 2.09 | 0.9 | 6.45 | 0.44 | 0.02 |
Asset Writedown | -35.22 | -11.47 | -6.05 | -36.45 | -1.39 |
Legal Settlements | - | - | -2.44 | -0.56 | - |
Other Unusual Items | - | 2.96 | 6.57 | 6.88 | -1.3 |
Pretax Income | 22.72 | -120.35 | -43.06 | -214.3 | 23.84 |
Income Tax Expense | 7.5 | -0.45 | 17.16 | -21.01 | 4.07 |
Earnings From Continuing Operations | 15.21 | -119.9 | -60.22 | -193.29 | 19.77 |
Minority Interest in Earnings | -0.68 | 2 | -2.98 | -5.01 | -1.2 |
Net Income | 14.53 | -117.9 | -63.2 | -198.3 | 18.57 |
Net Income to Common | 14.53 | -117.9 | -63.2 | -198.3 | 18.57 |
Net Income Growth | - | - | - | - | -88.57% |
Shares Outstanding (Basic) | 291 | 310 | 316 | 310 | 309 |
Shares Outstanding (Diluted) | 291 | 310 | 316 | 310 | 309 |
Shares Change (YoY) | -6.34% | -1.82% | 1.99% | 0.12% | 0.93% |
EPS (Basic) | 0.05 | -0.38 | -0.20 | -0.64 | 0.06 |
EPS (Diluted) | 0.05 | -0.38 | -0.20 | -0.64 | 0.06 |
EPS Growth | - | - | - | - | -88.68% |
Free Cash Flow | 85.77 | 30.55 | 36.2 | -15.56 | 100.69 |
Free Cash Flow Per Share | 0.29 | 0.10 | 0.12 | -0.05 | 0.33 |
Dividend Per Share | - | - | - | - | 0.040 |
Dividend Growth | - | - | - | - | 25.00% |
Gross Margin | 43.01% | 36.61% | 35.70% | 33.23% | 38.67% |
Operating Margin | 8.61% | -5.15% | -5.20% | -8.57% | 4.11% |
Profit Margin | 2.99% | -20.28% | -9.80% | -27.90% | 2.32% |
Free Cash Flow Margin | 17.64% | 5.26% | 5.62% | -2.19% | 12.59% |
EBITDA | 72.73 | 4.96 | 1.93 | -21.65 | 73.54 |
EBITDA Margin | 14.96% | 0.85% | 0.30% | -3.05% | 9.20% |
D&A For EBITDA | 30.88 | 34.87 | 35.43 | 39.26 | 40.65 |
EBIT | 41.85 | -29.91 | -33.5 | -60.91 | 32.89 |
EBIT Margin | 8.61% | -5.15% | -5.20% | -8.57% | 4.11% |
Effective Tax Rate | 33.03% | - | - | - | 17.08% |
Revenue as Reported | - | 581.33 | 644.62 | 710.77 | 799.83 |
Advertising Expenses | - | 17.77 | 24.75 | 25.27 | 30.74 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.